Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Тайверб/Tyverb (лапатиниб) – первый двойной анти-ErbB1(EGFR)- и анти-ErbB2(HER2)-ингибитор в лечении местно-распространенного и метастатического рака молочной железы зарегистрирован в Российской Федерации
Тайверб/Tyverb (лапатиниб) – первый двойной анти-ErbB1(EGFR)- и анти-ErbB2(HER2)-ингибитор в лечении местно-распространенного и метастатического рака молочной железы зарегистрирован в Российской Федерации
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Saez R, Molina MA, Ramsey EE et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424–31.
2. Chandarlapaty S, Scaltriti M, Baselga J et al. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. ASCO 2007, abstr. 10515.
3. Blackwell KL, Kaplan EH, Franco SX et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22 (14 Suppl.).
4. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
5. Sherrill B, Allshouse A, Amonkar M et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). ASCO 2007; abstr. 1026.
6. Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. ASCO 2007, abstr. 1035.
7. Lin NU, Dieras V, Paul D et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). ASCO 2007; abstr. 1012.
8. Gomez HL, Chavez MA, Doval DC et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. SABCS 2006; abstr. 1090.
9. Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. ASCO 2007; abstr. 1011.
10. Cristofanilli M, Boussen H, Baselga J. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res 2006; 100 (Suppl. 1): S5.
11. Crown JP, Burris HA, Jones S et al. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). ASCO 2007; abstr. 1027.
12. Семиглазов В.Ф., Иванов В.Г., Семиглазов В.В. и др. Биологически направленная терапия рака молочной железы. Рус. мед. журн. (Онкология). 2007; 25 (15): 1912–4.
13. Жукова Л.Г., Личиницер М.Р. Лапатиниб – ингибитор тирозинкиназ EGFR и HER2. Новые перспективы лечения больных с HER2 положительными опухолями. По материалам ASCO-2007. Фарматека, Онкология ASCO-2007; 18–23.
2. Chandarlapaty S, Scaltriti M, Baselga J et al. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. ASCO 2007, abstr. 10515.
3. Blackwell KL, Kaplan EH, Franco SX et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004; 22 (14 Suppl.).
4. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43.
5. Sherrill B, Allshouse A, Amonkar M et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). ASCO 2007; abstr. 1026.
6. Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. ASCO 2007, abstr. 1035.
7. Lin NU, Dieras V, Paul D et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). ASCO 2007; abstr. 1012.
8. Gomez HL, Chavez MA, Doval DC et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. SABCS 2006; abstr. 1090.
9. Di Leo A, Gomez H, Aziz Z et al. Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients. ASCO 2007; abstr. 1011.
10. Cristofanilli M, Boussen H, Baselga J. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res 2006; 100 (Suppl. 1): S5.
11. Crown JP, Burris HA, Jones S et al. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC). ASCO 2007; abstr. 1027.
12. Семиглазов В.Ф., Иванов В.Г., Семиглазов В.В. и др. Биологически направленная терапия рака молочной железы. Рус. мед. журн. (Онкология). 2007; 25 (15): 1912–4.
13. Жукова Л.Г., Личиницер М.Р. Лапатиниб – ингибитор тирозинкиназ EGFR и HER2. Новые перспективы лечения больных с HER2 положительными опухолями. По материалам ASCO-2007. Фарматека, Онкология ASCO-2007; 18–23.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.